Fumaric Acid

Fumaric Acid

SCHEMBL3701324

CNCc1cc(S(=O)(=O)c2ccc(C)nc2)n(-c2cccc(F)c2Cl)n1.O=C(O)/C=C/C(=O)O

nearest known ligand 0.34

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol

The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
MEN1 known ✓ O00255 1/20 0.30
KMT2A known ✓ Q03164 1/20 0.30
P2RX7 Q99572 2/20 0.34
NAMPT P43490 13/20 0.34
CYP2C9 P11712 1/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.30
SCN9A Q15858 1/20 0.30
PTGS2 P35354 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fumaric Acid SCHEMBL3701327 1.00 P2RX7 (0.34) P2RX7NAMPTCYP2C9PTGDR2MEN1
Fumaric Acid SCHEMBL3704597 0.93 NAMPT (0.35) NAMPTCYP2C9SCN9APTGS2
Fumaric Acid SCHEMBL3704601 0.93 NAMPT (0.35) NAMPTCYP2C9SCN9APTGS2
Fumaric Acid SCHEMBL4126459 0.92 NAMPT (0.35) NAMPTCYP2C9PTGS2
Fumaric Acid SCHEMBL4126452 0.92 NAMPT (0.35) NAMPTCYP2C9PTGS2
Fumaric Acid SCHEMBL4126782 0.92 NAMPT (0.35) NAMPTCYP2C9PTGS2
Fumaric Acid SCHEMBL4126776 0.92 NAMPT (0.35) NAMPTCYP2C9PTGS2
Fumaric Acid SCHEMBL4118248 0.89 NPC1 (0.35) NAMPT
Fumaric Acid SCHEMBL4118257 0.89 NPC1 (0.35) NAMPT
Fumaric Acid SCHEMBL3813537 0.88 NAMPT (0.35) NAMPTCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190822-B1 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-12-31 EP disclosed
EP-2190822-A2 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2010-06-02 EP disclosed
WO-2009041705-A9 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2009-08-13 WO disclosed
US-20090156642-A1 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
WO-2009041705-A2 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156642-A1 5-Membered heterocyclic compound CEL, PGA5, COG5 MEN1 1910/4885KMT2A 4776/4885P2RX7 1303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.